{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T07:41:04Z","timestamp":1706254864112},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,3,7]],"date-time":"2012-03-07T00:00:00Z","timestamp":1331078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1245\/s10434-012-2258-x","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T10:49:40Z","timestamp":1331030980000},"page":"1738-1744","source":"Crossref","is-referenced-by-count":9,"title":["Managing the Breast in Patients Who Test Positive for Hereditary Breast Cancer"],"prefix":"10.1245","volume":"19","author":[{"given":"David","family":"Euhus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,7]]},"reference":[{"issue":"5645","key":"2258_CR1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643\u20136.","journal-title":"Science."},{"key":"2258_CR2","doi-asserted-by":"crossref","first-page":"R833","DOI":"10.1186\/bcr1293","volume":"7","author":"J Kotsopoulos","year":"2005","unstructured":"Kotsopoulos J, Olopado OI, Ghadirian P, et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7:R833\u201343.","journal-title":"Breast Cancer Res."},{"key":"2258_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mc.20364","volume":"47","author":"J Brunet","year":"2008","unstructured":"Brunet J, Vazquez-Martin A, Colomer R, et al. BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinogen. 2008;47:157\u201363.","journal-title":"Mol Carcinogen."},{"key":"2258_CR4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the breast cancer linkage consortium. Am J Hum Genet. 1998;62:676\u201389.","journal-title":"Am J Hum Genet."},{"key":"2258_CR5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117\u201330.","journal-title":"Am J Hum Genet."},{"key":"2258_CR6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643\u20136.","journal-title":"Science."},{"key":"2258_CR7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1399-0004.2009.01328.x","volume":"77","author":"S Panchal","year":"2010","unstructured":"Panchal S, Bordeleau L, Poll A, et al. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation\u2013positive families? Clin Genet. 2010;77:273\u20139.","journal-title":"Clin Genet."},{"key":"2258_CR8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ijc.10666","volume":"102","author":"M Tilanus-Linthorst","year":"2002","unstructured":"Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. BRCA1\/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer. 2002;102:91\u20135.","journal-title":"Int J Cancer."},{"key":"2258_CR9","doi-asserted-by":"crossref","unstructured":"Greuter MJ, Jansen-van der Weide MC, Jacobi CE, et al. The validation of a simulation model incorporating radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk. Eur J Cancer. 2010;46:495\u2013504.","DOI":"10.1016\/j.ejca.2009.10.030"},{"key":"2258_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","volume":"351","author":"M Kriege","year":"2004","unstructured":"Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427\u201337.","journal-title":"N Engl J Med."},{"issue":"9473","key":"2258_CR11","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","volume":"365","author":"MO Leach","year":"2005","unstructured":"Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769\u201378.","journal-title":"Lancet."},{"key":"2258_CR12","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","volume":"292","author":"E Warner","year":"2004","unstructured":"Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317\u201325.","journal-title":"JAMA."},{"key":"2258_CR13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1148\/radiol.2423051965","volume":"242","author":"F Sardanelli","year":"2007","unstructured":"Sardanelli F, Podo F, D\u2019Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology. 2007;242:698\u2013715.","journal-title":"Radiology."},{"key":"2258_CR14","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1200\/JCO.2009.24.4277","volume":"27","author":"SP Weinstein","year":"2009","unstructured":"Weinstein SP, Localio AR, Conant EF, et al. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol. 2009;27:6124\u20138.","journal-title":"J Clin Oncol."},{"key":"2258_CR15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.breast.2007.01.006","volume":"16","author":"AI Hagen","year":"2007","unstructured":"Hagen AI, Kvistad KA, Maehle L, et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast. 2007;16:367\u201374.","journal-title":"Breast."},{"key":"2258_CR16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00330-009-1588-y","volume":"20","author":"K Kelly","year":"2010","unstructured":"Kelly K, Dean J, Comulada W, Lee SJ. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol. 2010;20:734\u201342.","journal-title":"Eur Radiol."},{"key":"2258_CR17","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast and ovarian. NCCN clinical practice guidelines in oncology v.1.2010, vol. 1. Fort Washington, PA: NCCN; 2010."},{"key":"2258_CR18","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371\u201388.","journal-title":"J Natl Cancer Inst."},{"key":"2258_CR19","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"MC King","year":"2001","unstructured":"King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA. 2001;286:2251\u20136.","journal-title":"JAMA."},{"key":"2258_CR20","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122:2017\u201322.","journal-title":"Int J Cancer."},{"key":"2258_CR21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475\u20139.","journal-title":"J Natl Cancer Inst."},{"key":"2258_CR22","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616\u201322.","journal-title":"N Engl J Med."},{"key":"2258_CR23","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"TR Rebbeck","year":"2005","unstructured":"Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23:7804\u201310.","journal-title":"J Clin Oncol."},{"key":"2258_CR24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331\u20137.","journal-title":"J Clin Oncol."},{"key":"2258_CR25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967\u201375.","journal-title":"JAMA."},{"key":"2258_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/gtmb.2008.0067","volume":"13","author":"MS Beattie","year":"2009","unstructured":"Beattie MS, Crawford B, Lin F, et al. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13:51\u20136.","journal-title":"Genet Test Mol Biomarkers."},{"key":"2258_CR27","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","volume":"18","author":"DG Evans","year":"2009","unstructured":"Evans DG, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev. 2009;18:2318\u201324.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"2258_CR28","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","volume":"14","author":"BA Heemskerk-Gerritsen","year":"2007","unstructured":"Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14:3335\u201344.","journal-title":"Ann Surg Oncol."},{"key":"2258_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"H Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159\u201364.","journal-title":"N Engl J Med."},{"key":"2258_CR30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"LC Hartmann","year":"1999","unstructured":"Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77\u201384.","journal-title":"N Engl J Med."},{"key":"2258_CR31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055\u201362.","journal-title":"J Clin Oncol."},{"key":"2258_CR32","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archsurg.143.11.1106","volume":"143","author":"JP Crowe","year":"2008","unstructured":"Crowe JP, Patrick RJ, Yetman RJ, Djohan R. Nipple-sparing mastectomy update: one hundred forty-nine procedures and clinical outcomes. Arch Surg. 2008;143:1106\u201310.","journal-title":"Arch Surg."},{"key":"2258_CR33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/SLA.0b013e31818e41a7","volume":"249","author":"ER Garwood","year":"2009","unstructured":"Garwood ER, Moore D, Ewing C, et al. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg. 2009;249:26\u201332.","journal-title":"Ann Surg."},{"key":"2258_CR34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-2008-1038774","volume":"40","author":"O Scheufler","year":"2008","unstructured":"Scheufler O, Fritschen U. Prophylactic mastectomy in women at high risk for breast cancer: indications and options. Handchir Mikrochir Plast Chir. 2008;40:239\u201347.","journal-title":"Handchir Mikrochir Plast Chir."},{"key":"2258_CR35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.anplas.2007.09.004","volume":"53","author":"MC Missana","year":"2008","unstructured":"Missana MC, Chompret A. Prophylactic mastectomies and immediate breast reconstruction in patients at very high genetic risk: our experience with 14 cases. Ann Chir Plast Esthet. 2008;53:325\u201333.","journal-title":"Ann Chir Plast Esthet."},{"key":"2258_CR36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(05)70210-2","volume":"6","author":"KA Metcalfe","year":"2005","unstructured":"Metcalfe KA, Semple JL, Narod SA. Time to reconsider subcutaneous mastectomy for breast-cancer prevention? Lancet Oncol. 2005;6:431\u20134.","journal-title":"Lancet Oncol."},{"key":"2258_CR37","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633\u20137.","journal-title":"J Natl Cancer Inst."},{"key":"2258_CR38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.2008.21.7588","volume":"28","author":"J Zakhireh","year":"2010","unstructured":"Zakhireh J, Fowble B, Esserman LJ. Application of screening principles to the reconstructed breast. J Clin Oncol. 2010;28:173\u201380.","journal-title":"J Clin Oncol."},{"key":"2258_CR39","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1200\/JCO.2007.13.9568","volume":"26","author":"Y Brandberg","year":"2008","unstructured":"Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26:3943\u20139.","journal-title":"J Clin Oncol."},{"issue":"9193","key":"2258_CR40","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(99)04336-6","volume":"354","author":"H Jernstrom","year":"1999","unstructured":"Jernstrom H, Lerman C, Ghadirian P, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999;354(9193):1846\u201350.","journal-title":"Lancet."},{"key":"2258_CR41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.21273","volume":"117","author":"CA Cullinane","year":"2005","unstructured":"Cullinane CA, Lubinski J, Neuhausen SL, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1\/BRCA2 mutation carriers. Int J Cancer. 2005;117:988\u201391.","journal-title":"Int J Cancer."},{"key":"2258_CR42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jnci\/djj132","volume":"98","author":"N Andrieu","year":"2006","unstructured":"Andrieu N, Goldgar DE, Easton DF, et al. Pregnancies, breast-feeding, and breast cancer risk in the international BRCA1\/2 carrier cohort study (IBCCS). J Natl Cancer Inst. 2006;98:535\u201344.","journal-title":"J Natl Cancer Inst."},{"key":"2258_CR43","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/bcr1630","volume":"8","author":"A Antoniou","year":"2006","unstructured":"Antoniou A, Shenton A, Maher E, et al. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2006;8:R72.","journal-title":"Breast Cancer Res."},{"key":"2258_CR44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00001648-200205000-00004","volume":"13","author":"P Hartge","year":"2002","unstructured":"Hartge P, Chatterjee N, Wacholder S, et al. Breast cancer risk in Ashkenazi BRCA1\/2 mutation carriers: effects of reproductive history. Epidemiology. 2002;13:255\u201361.","journal-title":"Epidemiology."},{"key":"2258_CR45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejca.2006.07.019","volume":"43","author":"FP Liebens","year":"2007","unstructured":"Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1\/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer. 2007;43:238\u201357.","journal-title":"Eur J Cancer."},{"key":"2258_CR46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-010-0894-z","volume":"121","author":"LJ Pierce","year":"2010","unstructured":"Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121:389\u201398.","journal-title":"Breast Cancer Res Treat."},{"issue":"9316","key":"2258_CR47","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0140-6736(02)08434-9","volume":"359","author":"BG Haffty","year":"2002","unstructured":"Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1\/2 status. Lancet. 2002;359(9316):1471\u20137.","journal-title":"Lancet."},{"key":"2258_CR48","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1245\/s10434-009-0638-7","volume":"16","author":"CA Garcia-Etienne","year":"2009","unstructured":"Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1\/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16:3380\u20137.","journal-title":"Ann Surg Oncol."},{"key":"2258_CR49","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887\u201392.","journal-title":"J Clin Oncol."},{"issue":"9245","key":"2258_CR50","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","volume":"356","author":"SA Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356(9245):1876\u201381.","journal-title":"Lancet."},{"key":"2258_CR51","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"K Metcalfe","year":"2004","unstructured":"Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328\u201335.","journal-title":"J Clin Oncol."},{"key":"2258_CR52","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"LJ Pierce","year":"2006","unstructured":"Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer. J Clin Oncol. 2006;24:2437\u201343.","journal-title":"J Clin Oncol."},{"key":"2258_CR53","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","volume":"118","author":"J Gronwald","year":"2006","unstructured":"Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281\u20134.","journal-title":"Int J Cancer."},{"key":"2258_CR54","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","volume":"26","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093\u20137.","journal-title":"J Clin Oncol."},{"key":"2258_CR55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2006.07.3890","volume":"25","author":"KP Tercyak","year":"2007","unstructured":"Tercyak KP, Peshkin BN, Brogan BM, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1\/2 gene testing. J Clin Oncol. 2007;25:285\u201391.","journal-title":"J Clin Oncol."},{"key":"2258_CR56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375\u20139.","journal-title":"J Clin Oncol."},{"key":"2258_CR57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123\u201334.","journal-title":"N Engl J Med."},{"key":"2258_CR58","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785\u201390.","journal-title":"J Clin Oncol."},{"key":"2258_CR59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2009.04.008","volume":"47","author":"A Peralta-Leal","year":"2009","unstructured":"Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med. 2009;47:13\u201326.","journal-title":"Free Radic Biol Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-012-2258-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2258-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:46:33Z","timestamp":1572954393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-012-2258-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,7]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["2258"],"URL":"https:\/\/doi.org\/10.1245\/s10434-012-2258-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,7]]}}}